Search Results - David W. End

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas

    Phase I Trial and Pharmacokinetic Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibr... by Brigitte C. Widemann, Wanda L. Salzer, R.J. Arceci, Susan M. Blaney, Elizabeth Fox, David W. End, Andrea Gillespie, Patricia Whitcomb, Joseph S. Palumbo, Aaron Pitney, Nalini Jayaprakash, Peter Zannikos, Frank M. Balis

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

    Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial by Judith E. Karp, Jeffrey E. Lancet, Scott H. Kaufmann, David W. End, James R. Wright, Kees Bol, Ivan D. Horak, Michael L. Tidwell, Jane L. Liesveld, Timothy Kottke, Dawn Ange, Laxmi Narayana Buddharaju, Ivana Gojo, W. Edward Highsmith, R. T. Belly, Raymond J. Hohl, Mary Ellen Rybak, Alain Thibault, Joseph D. Rosenblatt

    Published 2001
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: